Showing results (71-80 of 79) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Journal of the American College of Cardiology|March 5, 2004
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapyGreetje J de Grooth, Kim E Zerba, Shu-Pang Huang, et al.Depression and Anxiety|May 11, 2010
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorderVladimir Coric, Howard H Feldman, Dan A Oren, et al.Journal of Hepatology|January 22, 2014
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null respondersAnna S Lok, David F Gardiner, Christophe Hézode, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2015
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patientsGregory T Everson, Karen D Sims, Paul J Thuluvath, et al.Nature Medicine|May 15, 2020
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitorsKurt A Schalper, Michael Carleton, Ming Zhou, et al.Antimicrobial Agents and Chemotherapy|February 1, 2012
Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis CClaudio Pasquinelli, Fiona McPhee, Timothy Eley, et al.Gastroenterology|November 5, 2013
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infectionGregory T Everson, Karen D Sims, Maribel Rodriguez-Torres, et al.The New England Journal of Medicine|January 17, 2014
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infectionMark S Sulkowski, David F Gardiner, Maribel Rodriguez-Torres, et al.The Journal of Pharmacology and Experimental Therapeutics|January 1, 2013
Pharmacodynamics of selective inhibition of γ-secretase by avagacestatCharles F Albright, Randy C Dockens, Jere E Meredith, et al.Pageof 8